Nature Reviews Gastroenterology & Hepatology
Cure8 research brief
Relieving IBD with duvakitug
Medications
Phase 2 clinical trial
Adult patients
Patients On Biologics
Clinicians
Researchers
Crohn's disease
Ulcerative colitis
Why This Matters
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials confirm efficacy and safety.
Who Should Pay Attention
Adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, patients considering biologic options, clinicians who treat IBD, and researchers studying TL1A or novel IBD therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
The RELIEVE UCCD programme included two parallel 14‑week, dose‑ranging phase IIb randomized placebo‑controlled trials testing 450 mg and 900 mg doses of duvakitug in adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis using a shared master protocol.
In Crohn’s disease the reported endoscopic response at week 14 was higher with duvakitug (26% at 450 mg, 48% at 900 mg) than placebo (13%). In ulcerative colitis the reported clinical remission rates at week 14 were 36% (450 mg) and 48% (900 mg) versus 20% for placebo. The article notes no major safety concerns in these phase IIb cohorts.
Larger phase III trials have been initiated. Key practical point: These are phase IIb results summarized in a journal article; they indicate promise but do not establish long‑term benefit, optimal dosing, comparative effectiveness, or rare safety risks. Await published full phase III data for confirmation and regulatory decisions.
Keep In Mind
These findings come from phase IIb randomized trials reported in a review article; phase III trials are underway and are needed to confirm efficacy, safety, and long‑term outcomes. The summary is based on the article’s reported trial results rather than full regulatory assessments.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationNature Reviews Gastroenterology & Hepatology
AuthorsKatrina Ray
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Johnson & Johnson advances IBD therapy, despite trial miss
This affects people with IBD because it describes late-stage testing decisions for a combination biologic therapy that targets ulcerative colitis and Crohn’s disease. If pursued, the approach could change future...
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
A new FDA approval expands treatment options for adults with moderate-to-severe Crohn's disease and means mirikizumab (Omvoh) is now approved for both Crohn's disease and ulcerative colitis. The decision was based on...